EP2026659A4 - COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER - Google Patents

COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER

Info

Publication number
EP2026659A4
EP2026659A4 EP07798274A EP07798274A EP2026659A4 EP 2026659 A4 EP2026659 A4 EP 2026659A4 EP 07798274 A EP07798274 A EP 07798274A EP 07798274 A EP07798274 A EP 07798274A EP 2026659 A4 EP2026659 A4 EP 2026659A4
Authority
EP
European Patent Office
Prior art keywords
compounds
treatment
metabolic disorders
metabolic
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07798274A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2026659A2 (en
Inventor
Shalini Sharma
Borstel Reid W Von
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of EP2026659A2 publication Critical patent/EP2026659A2/en
Publication of EP2026659A4 publication Critical patent/EP2026659A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07798274A 2006-06-09 2007-06-08 COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER Ceased EP2026659A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80433606P 2006-06-09 2006-06-09
PCT/US2007/070691 WO2007146768A2 (en) 2006-06-09 2007-06-08 Compounds for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
EP2026659A2 EP2026659A2 (en) 2009-02-25
EP2026659A4 true EP2026659A4 (en) 2010-06-30

Family

ID=38832700

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07798274A Ceased EP2026659A4 (en) 2006-06-09 2007-06-08 COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER

Country Status (12)

Country Link
US (1) US20100234464A1 (enExample)
EP (1) EP2026659A4 (enExample)
JP (1) JP5252585B2 (enExample)
KR (1) KR101391905B1 (enExample)
CN (1) CN101466266A (enExample)
AU (1) AU2007257854B2 (enExample)
CA (1) CA2654530A1 (enExample)
IL (1) IL195392A0 (enExample)
MX (1) MX2008015640A (enExample)
NZ (1) NZ573031A (enExample)
WO (1) WO2007146768A2 (enExample)
ZA (1) ZA200809774B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2240024A4 (en) * 2008-01-15 2014-05-21 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
CA2716860C (en) 2008-03-13 2017-08-29 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
EP4548898A1 (en) 2022-07-01 2025-05-07 The University of Tokyo Body surface ulcer healing promoting device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100341A2 (en) * 2001-06-12 2002-12-19 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004073611A2 (en) * 2003-02-13 2004-09-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004091486A2 (en) * 2003-04-15 2004-10-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123665T2 (de) * 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
AU2003286728A1 (en) * 2002-11-01 2004-06-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2521589C (en) * 2003-04-22 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR101192272B1 (ko) * 2003-04-30 2012-10-17 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
WO2005018628A1 (en) * 2003-08-20 2005-03-03 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009531280A (ja) * 2006-01-25 2009-09-03 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
EP1976378A4 (en) * 2006-01-25 2010-06-09 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100341A2 (en) * 2001-06-12 2002-12-19 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004073611A2 (en) * 2003-02-13 2004-09-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004091486A2 (en) * 2003-04-15 2004-10-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROOST J H ET AL: "MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring", COMPUTERS IN BIOLOGY AND MEDICINE, NEW YORK, NY, US LNKD- DOI:10.1016/0010-4825(92)90011-B, vol. 22, no. 3, 1 May 1992 (1992-05-01), pages 155 - 163, XP022874706, ISSN: 0010-4825, [retrieved on 19920501] *

Also Published As

Publication number Publication date
CN101466266A (zh) 2009-06-24
ZA200809774B (en) 2010-10-27
WO2007146768A3 (en) 2008-02-21
IL195392A0 (en) 2009-08-03
WO2007146768A2 (en) 2007-12-21
AU2007257854A1 (en) 2007-12-21
AU2007257854B2 (en) 2012-04-12
JP5252585B2 (ja) 2013-07-31
JP2009539877A (ja) 2009-11-19
EP2026659A2 (en) 2009-02-25
NZ573031A (en) 2011-11-25
KR101391905B1 (ko) 2014-05-07
KR20090018795A (ko) 2009-02-23
US20100234464A1 (en) 2010-09-16
MX2008015640A (es) 2009-01-09
CA2654530A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
EP2056673A4 (en) COMBINATION TREATMENT FOR METABOLISM DISEASES
EP2091955A4 (en) ALKOXY COMPOUNDS FOR THE TREATMENT OF DISEASES
EP2001461A4 (en) COMBINATION TREATMENT FOR METABOLISM DISEASES
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP2340242A4 (en) COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
ZA200808963B (en) Compounds for the treatment of metabolic disorders
EP2148691A4 (en) LOCAL COMPLEMENTAL INHIBITION FOR THE TREATMENT OF COMPLEMENT-MEDIATED DISEASES
EP2118074A4 (en) COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIAC DISEASES
IL192691A0 (en) Hydantoin compounds for the treatment of inflammatory disorders
EP2051967A4 (en) BENZIMIDAZOLE DERIVATIVES SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO THE VALLINOID RECEPTOR TRPV1
IL190920A0 (en) Compounds for the treatment of metabolic disorders
EP2323641A4 (en) NYASOL AND ANALOGUE THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR-BETA-MEDIATED ILLNESSES
EP2035369A4 (en) THERAPEUTIC COMPOUNDS
ZA200805645B (en) Compounds for the treatment of metabolic disorders
EP1993589A4 (en) TREATMENTS FOR NEUROLOGICAL DISEASES
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
EP2474543A4 (en) THERAPEUTIC AGENT FOR DEPRESSIVE ATHIBITIONS
EP2349320A4 (en) COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES
EP2328584A4 (en) TREATMENT OF NEUROLOGICAL DISEASES WITH HUPERZIN
EP1991246A4 (en) TREATMENT OF DEVELOPMENTAL DISTURBANCES
EP2026659A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
EP2328877A4 (en) 1,4-BENZOXAZINE COMPOUNDS AND DERIVATIVES THEREOF AS THERAPEUTIC ACTIVITIES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
IL192851A0 (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124486

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100528

17Q First examination report despatched

Effective date: 20110128

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20140121

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1124486

Country of ref document: HK